Gene therapy holds the promise of revolutionizing the way we treat diseases. By using recombinant DNA and oligonucleotides (ONs), gene functions can be restored, altered or silenced according to the therapeutic need. However, gene therapy approaches require the delivery of large and charged nucleic acid-based molecules to their intracellular targets across the plasma membrane, which is inherently impermeable to such molecules. In this thesis, two chemically modified cell-penetrating peptides (CPPs) that have superior delivery properties for several nucleic acid-based therapeutics are developed. These CPPs can spontaneously form nanoparticles upon non-covalent complexation with the nucleic acid cargo, and the formed nanoparticles mediate efficient cellular transfection. In paper I, we show that an N-terminally stearic acid-modified version of transportan-10 (PF3) can efficiently transfect different cell types with plasmid DNA and mediates efficient gene delivery in-vivo when administrated intra muscularly (i.m.) or intradermaly (i.d.). In paper II, a new peptide with ornithine modification, PF14, is shown to efficiently deliver splice-switching oligonucleotides (SSOs) in different cell models including mdx mouse myotubes; a cell culture model of Duchenne’s muscular dystrophy (DMD). Additionally, we describe a method for incorporating the PF14-SSO nanoparticles into a solid formulation that is active and stable even when stored at elevated temperatures for several weeks. In paper III, we demonstrate the involvement of class-A scavenger receptor subtypes (SCARA3 & SCARA5) in the uptake of PF14-SSO nanoparticles, which possess negative surface charge, and suggest for the first time that some CPP-based systems function through scavenger receptors. In paper IV, the ability of PF14 to deliver siRNA to different cell lines is shown and their stability in simulated gastric acidic conditions is highlighted. Taken together, these results demonstrate that certain chemical modifications can drastically enhance the activity and stability of CPPs for delivering nucleic acids after spontaneous nanoparticle formation upon non-covalent complexation. Moreover, we show that CPP-based nanoparticles can be formulated into convenient and stable solid formulations that can be suitable for several therapeutic applications. Importantly, the involvement of scavenger receptors in the uptake of such nanoparticles is presented, which could yield novel possibilities to understand and improve the transfection by CPPs and other gene therapy nanoparticles. / At the time of doctoral defence the following paper was unpublished and had a status as follows: Paper nr 4: Submitted

Alzheimer’s disease is the most common form of dementia. It is a neurodegenerative disorder characterized by extracellular senile plaques and intracellular neurofibrillary tangles. The main constituent of the senile plaques is the neurotoxic β-amyloid peptide. Surrounding the senile plaques are activated astrocytes and microglia, believed to contribute to neurotoxicity through secretion of proinflammatory cytokines, like interleukin-1β and interleukin-6. For many inflammatory actions, including the cytokine induction in glial cells, the transcription factor NFκB plays a key role. This suggests that therapeutical strategies aimed to control the development of Alzheimer’s disease could include administration of drugs that hinder NFκB activation. The major aim of this thesis was to examine the effects of β-amyloid together with interleukin-1β on cytokine expression as well as NFκB activation in glial cells. The possibility to block NFκB activation, and downstream effects like interleukin-6 expression, by using an NFκB decoy was investigated. The possibility to improve the cellular uptake of the decoy by linking it to a cell-penetrating peptide was also investigated. The results obtained provide supportive evidence that inflammatory cytokines are induced by β-amyloid, and that they can indeed potentiate its effects. The results further demonstrate that by blocking NFκB activation, the induction of interleukin-6 expression can be inhibited. By using an improved cellular delivery system, the uptake of the NFκB decoy and hence the downstream cytokine inhibition could be increased. In conclusion, these results demonstrate the possibility to decrease the inflammatory reactions taken place in Alzheimer’s disease brains, which may ultimately lead to a possible way of controlling this disorder.

Delivery of macromolecules into mammalian cells in vitro and in vivo has enabled new areas of research and offers the potential for powerful new treatment options. Recent research has generated many delivery platforms but these solutions remain limited by scope, potency and safety. We have reported a superpositively charged green fluorescent protein (+36 GFP) with the ability to deliver nucleic acids into a variety of mammalian cell lines in vitro and to potently deliver protein in vitro and in vivo without toxicity. These results have directed us to identify a subset of naturally occurring human proteins with similar but previously unknown cell-penetrating and protein delivery properties. Preliminary efforts have been made towards establishing the therapeutic potential for supercharged proteins replacement of the cytosolic enzyme, argininosuccinate synthase. Preliminary efforts have also been made towards enhancing endosomal escape with \(His_{39} GFP\).

Adenovirus serotype 5 (Ad5) is widely used as an oncolytic agent for cancer therapy. However, its infectivity is highly dependent on the expression level of coxsackievirus-adenovirus receptor (CAR) on the surface of tumor cells. We engineered Ad5 virus with the protein transduction domain (PTD) from the HIV-1 Tat protein (Tat-PTD) inserted in the hypervariable region 5 (HVR5) of the hexon protein in the virus capsid. Tat-PTD-modified Ad5 shows a dramatically increased transduction level of CAR-negative cells and bypassed fiber-mediated transduction. It also overcomes the fiber-masking problem, which is caused by release of excess fiber proteins from infected cells. To achieve specific viral replication in neuroblastoma and neuroendocrine tumor cells, we identified the secretogranin III (SCG3) promoter and constructed an adenovirus Ad5PTD(ASH1-SCG3-E1A) wherein E1A gene expression is controlled by the SCG3 promoter and the achaete-scute complex homolog 1 (ASH1) enhancer. This virus shows selective and efficient killing of neuroblastoma cell lines in vitro, and delays human neuroblastoma xenograft tumor growth on nude mice. To further enhance the viral oncolytic efficacy, we also switched the fiber 5 to fiber 35 to generate Ad5PTDf35. This vector shows dramatically increased transduction capacity of primary human cell cultures including hematopoietic cells and their derivatives, pancreatic islets and exocrine cells, mesenchymal stem cells and primary tumor cells including primary cancer initiating cells. Ad5PTDf35-based adenovirus could be a useful platform for gene delivery and oncolytic virus development. Viral oncolysis alone cannot completely eradicate tumors. Therefore, we further armed the Ad5PTDf35-D24 virus with a secreted form of Helicobacter pylori Neutrophil Activating Protein (HP-NAP). Expression of HP-NAP recruits neutrophils to the site of infection, activates an innate immune response against tumor cells and provokes a Th1-type adaptive immune response. Established tumor on nude mice could be completely eradicated in some cases after treatment with this virus and the survival of mice was significantly prolonged.

Conjugation of the Human Immunodeficiency Virus Transactivator of Transcription (TAT) to active proteins allows transport into the intracellular environment. This feature can be harnessed to deliver combinations of reprogramming factors (RFs) such as c-Myc, Oct4, Klf4 and Sox2 into somatic cells to derive induced pluripotent stem cells (iPSCs). For this project, TAT-fusion proteins including four TAT-conjugated RFs (TAT-RFs) have been produced and purified. All four TAT-RFs can bind specific DNA sequences. Bioactivity was tested in live cells using a novel assay based on an engineered fibroblast cell line that can be induced to express RFs by doxycycline and subsequently generate iPSCs. To test each TAT-RF, reprogramming was blocked by transient silencing of a single RF by siRNA and rescued by the corresponding TAT-RF. The results of this assay suggested that TAT-Klf4 was bioactive in cells; however, definitive evidence could not be obtained for other RFs.

Conjugation of the Human Immunodeficiency Virus Transactivator of Transcription (TAT) to active proteins allows transport into the intracellular environment. This feature can be harnessed to deliver combinations of reprogramming factors (RFs) such as c-Myc, Oct4, Klf4 and Sox2 into somatic cells to derive induced pluripotent stem cells (iPSCs). For this project, TAT-fusion proteins including four TAT-conjugated RFs (TAT-RFs) have been produced and purified. All four TAT-RFs can bind specific DNA sequences. Bioactivity was tested in live cells using a novel assay based on an engineered fibroblast cell line that can be induced to express RFs by doxycycline and subsequently generate iPSCs. To test each TAT-RF, reprogramming was blocked by transient silencing of a single RF by siRNA and rescued by the corresponding TAT-RF. The results of this assay suggested that TAT-Klf4 was bioactive in cells; however, definitive evidence could not be obtained for other RFs.

Les peptides pénétrants (CPP) se caractérisent par deux propriétés : ils pénètrent dans l'espace intracellulaire et favorisent l'internalisation de cargaisons moléculaires auxquelles ils sont associés. Si les CPP sont très utilisés comme vecteurs en recherche fondamentale, la méconnaissance des mécanismes de pénétration et de leurs distributions intracellulaires limite leur utilisation thérapeutique. Il est admis que les CPP et leurs cargaisons sont internalisés par transport actif (endocytose) et par transport passif (translocation directe). J'ai étudié la translocation directe à l'échelle moléculaire en utilisant des membranes modèles. Les CPP usuels sont internalisés et permettent l'accumulation de cargaisons dans des vésicules unilamellaires. J'ai alors démontré que la translocation directe se déroule via la formation de complexes neutres et hydrophobes CPP-phospholipides.La pénétration intracellulaire des CPP est le plus souvent étudiée par microscopie confocale. J'ai démontré que des fortes concentrations locales de CPP induit une auto-inhibition de leur fluorophore. Cet artefact a conduit à des erreurs d'interprétation dans la littérature quant à la localisation des CPP. Un protocole permettant de révéler la fluorescence éteinte a été proposé et conduit à réévaluer la localisation subcellulaire des CPP ainsi que l'importance relative des mécanismes d'internalisation.Ces résultats ont permis de développer rationnellement de nouveaux vecteurs pénétrants : les oligoarginines acylées par des chaînes grasses dont des insaturations sont de stéréochimie cis. Leur internalisation passive particulièrement importante conduit à la libération de la cargaison dans le cytosol. / Cell penetrating peptides (CPPs) are short cationic sequences capable of shuttling bioactive cargoes into eukaryotic cells. If CPPs are common delivery tools in basic research, their therapeutic use is currently limited because their internalization mechanisms and intracellular distributions remain to be elucidated. In living cells there is evidence for both endocytosis of the CPPs and for “direct translocation”, an energy-independent uptake pathway. I analyzed the direct translocation phenomenon at the molecular level with model membranes. CPPs are internalized into large unilamellar vesicles and trigger the internalization of various cargoes. I then demonstrated that direct translocation occurs through membranes via the formation of a neutral and hydrophobic CPP-anionic phospholipids complex. CPPs internalization is mostly analyzed by confocal microscopy. I demonstrated that fluorescence self-quenching occurs if fluorescently labeled CPPs are locally too concentrated. This severe artifact led to misinterpretation of the subcellular distribution of CPPs. I developed a reliable procedure to avoid this artifact and ranked subcellular regions of living cells depending on their CPP concentration. As a result, I was able to rationalize the subcellular distribution of CPPs and to deduce their penetration mechanisms. The studies that I performed provided valuable information that I used to design a new family of delivery vectors: minimalist oligoarginines peptides acylated by unsaturated fatty acids (cis unsaturations). The direct translocation of these lipopeptides is particularly important yielding to an efficient delivery of a cargo inside the cytosol of living cells.

L’objectif du projet est de comprendre l’effet du peptide vecteur (R/W)9 sur les cellules tumorales EF, modèles du sarcome d’Ewing. En effet, ce peptide a la capacité de remodeler le cytosquelette d’actine dans ces cellules, ainsi que de réduire leur motilité et leur aptitude à croître en indépendance d’ancrage (Delaroche D. JBC 2010).La première étape de ce travail a été la caractérisation in vitro de l’interaction directe avec l’actine par cross-linking chimique et spectrométrie de masse (Clavier S. EuProt 2014). Ensuite, pour avancer dans la compréhension de l’effet du peptide (R/W)9, deux approches ont été développées.La première approche, basée sur du photocross-linking in cellulo ou in lysat, vise à identifier des partenaires intracellulaires du peptide vecteur. Pour cela, nous avons mis au point et validé biologiquement une version photoactivable du peptide (R/W)9. Puis, avant de passer sur cellules entières, nous nous sommes assurés de la faisabilité de la réaction de photocross-linking in vitro sur un système d’interaction modèle que nous avons également utilisé pour développer un logiciel capable d’interpréter les spectres MS/MS d’espèces photocross-linkées (Xlink-Identifier, Collaboration Dr Du X). Des expériences de purification d’affinité ont également été menées en immobilisant le peptide (R/W)9 sur des billes de streptavidine ensuite mises en présence de lysat cellulaire. Les protéines capturées ont été identifiées par spectrométrie de masse haut-débit. La seconde approche est de la protéomique différentielle avec un marquage SILAC et a pour objectif de mettre en évidence l’influence du peptide vecteur sur l’expression des protéines. / The aim of the project is to understand the effect of (R/W)9 cell penetrating peptide (CPP) on EF tumoral cells, an Ewing sarcoma model cell line. Actually, this peptide is able to remodel the actin cytoskeleton of these cells, to decrease their motility as well as their ability to grow without anchorage (Delaroche D. JBC 2010).The first step of this work was to characterize the in vitro interaction with actin using chemical cross-linking and mass spectrometry (Clavier S. Euprot 2014). Then, in order to get a deeper understanding of (R/W)9 peptide effect, two approaches were developed. The goal of the first approach based on in cellulo or in lysate photocross-linking is to identify (R/W)9 CPP’s partners. To do this, we designed and biologically validated a photoactivable version of (R/W)9 peptide. Then, before starting to work with living cells, we checked the feasibility of in vitro photocross-linking on a model interacting system that we also used to develop a software able to interpret MS/MS spectra of photocross-linked species. (Xlink-Identifier, Collaboration with Dr. X. Du.). Affinity purification experiments were also performed by incubating streptavidin magnetic beads bearing (R/W)9 peptide with cell lysates. Captured proteins were identified using high-throughput mass spectrometry. The second approach is differential proteomic with SILAC labelling and aims at assessing the influence of (R/W)9 CPP on proteins expression.

The cell membrane is an impermeable barrier for most macromolecules. Recently discovered cell-penetrating peptides (CPPs) have gained lot of attention because they can cross the membrane, and even more, carry cargoes with them. How CPPs enter cells is still not clear, while the delivery of different cargoes has been convincingly shown. This thesis concentrates on evaluating CPPs as vectors for different biologically relevant cargoes. Proposed internalisation mechanisms are reviewed as well as cargo coupling strategies. Biological activities of antisense oligonucleotides delivered by CPPs have been of particular interest and are explained in greater details. A new CPP, pIsl, was derived from Islet-1 transcription factor, and compared to archetypical CPPs like penetratin and transportan. All three peptides resided in the headgroup region of lipid bilayers in model membranes. However, penetratin and pIsl did only interact with negatively charged membranes, while transportan did not distinguish negatively charged and neutral membranes. This suggests different translocation pathways for different CPPs. Biotinylated pIsl and penetratin were complexed with avidin, and uptake of avidin into the human melanoma cell line Bowes was observed in both cases. This means that the protein is not unfolded during the translocation process, which is important in delivery of other, biologically active proteins. Transportan and its analogue TP10 were used for peptide nucleic acid (PNA) antisense oligonucleotide delivery. First, eight human galanin receptor type 1 targeting PNA oligomers were designed, conjugated to transportan and assayed for antisense efficiency. In contrary to avidin-biotinylated peptide conjugate, a covalent bond between PNA oligomers and the transport peptide was necessary for cellular uptake of oligomers. A common problem in antisense technology is inactivity of antisense oligonucleotides due to the secondary structure of the target. Efficiencies of tested galanin receptor type 1 targeting PNA oligomers varied over two orders of magnitude. The most efficient oligomers were targeting coding sequence regions 24-38 and 27-38, and had EC50 values 70 and 80 nM, respectively. TP10-antisense PNA oligomer conjugates were targeted also to L-type voltage dependent Ca2+ channel subunits CaV1.2 and CaV1.3. Specific down-regulation of respective proteins was demonstrated by immunohistochemistry. Physiological response to the down-regulation of either of Ca2+ channels was studied by alteration of flexor reflex sensitisation. Rats treated with either of the antisense PNA, but not with scrambled PNA lost the action potential windup phenomenon. In conjunction with a variety of drugs, modulating the conductivity and excitability of neuronal membranes, a central role of L-type CaV channels in sensitisation was confirmed. Nevertheless, also N-methyl-D-aspartate and glycine receptors were found to be required. Finally, delivery of plasmids by TP10 was evaluated. In contrary to many similar CPPs, TP10 was incapable to translocate plasmids to cells. However, addition of TP10 or a TP10-PNA conjugate to polyethyleneimine-condensed plasmids increased the expression of reporter genes. In summary, different types of cargoes have been delivered by CPPs and different cargo coupling strategies have been used. CPP-mediated antisense oligonucleotide delivery has been used to identify accessible sites in human galanin receptor type 1 mRNA and to determine the role of L-type voltage dependent Ca2+ channels in axon potential windup.

Oligonucleotide-based drugs hold great promise for the treatment of many types of diseases, ranging from genetic disorders to viral infections and cancer. The problem is that efficient delivery across the cell membrane is required for oligonucleotides to have their desired effect. Cell-penetrating peptides (CPPs) provide a solution to this problem. CPPs are capable of transporting cargoes such as drugs or nucleic acids for gene therapy into the cell, either by covalent conjugation to the cargo or by non-covalent complex formation. This thesis is focused on the development of a class of peptides called PepFects, peptides with fatty acid modifications capable of forming nanoparticle-sized complexes with oligonucleotides. These complexes are efficiently internalized by many different cell types and are generally non-toxic and non-immunogenic. We have developed a number of novel PepFect peptides and a quantitative structure-activity model to predict the biological effect of our peptides. In addition, the involvement of scavenger receptors class A in the endocytic uptake of PepFect complexes as well as other CPPs and polymeric transfection agents was studied. Lastly, we have developed a series of PepFect peptides for delivery across the blood-brain barrier and a model system mimicking the blood-brain barrier in order to evaluate the passage of these peptides. The general aim of this thesis is to improve the understanding of intracellular delivery of oligonucleotides with PepFect peptides from both a chemical and a biological viewpoint, and further improve the efficacy of this delivery system with the long-term goal of making it useful in clinical settings.